The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

about

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

Item

http://www.wikidata.org/entity/Q50050590

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@en

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@nl

type

Item

label

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@en

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@nl

prefLabel

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@en

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@nl

P1476

The role of palliative chemotherapy for terminally ill patients with advanced NSCLC.

@en

P2093

Dan Yang

http://www.w3.org/2001/XMLSchema#string

Dong-Yu Zhang

http://www.w3.org/2001/XMLSchema#string

Li-Qun Zou

http://www.w3.org/2001/XMLSchema#string

Meng Qiu

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xi Yan

http://www.w3.org/2001/XMLSchema#string

Yu Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Cancer statistics, 2010

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.

10-year update on chemotherapy for non-small cell lung cancer.

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

P304

153-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1759-7714.2012.00148.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260733623

http://www.w3.org/2001/XMLSchema#string

P698

28920200

http://www.w3.org/2001/XMLSchema#string